Panmure Gordon Reaffirms Buy Rating for Midatech Pharma PLC (MTPH)
Midatech Pharma PLC (LON:MTPH)‘s stock had its “buy” rating reaffirmed by stock analysts at Panmure Gordon in a research report issued on Wednesday. They currently have a GBX 380 ($4.96) price target on the stock. Panmure Gordon’s price objective points to a potential upside of 164.81% from the stock’s previous close.
Separately, N+1 Singer lowered their target price on shares of Midatech Pharma PLC from GBX 385 ($5.03) to GBX 300 ($3.92) and set a “buy” rating on the stock in a research note on Wednesday, June 1st.
Midatech Pharma PLC (LON:MTPH) traded down 2.71% on Wednesday, reaching GBX 143.50. 18,376 shares of the company’s stock traded hands. Midatech Pharma PLC has a 52-week low of GBX 100.51 and a 52-week high of GBX 285.00. The firm’s 50-day moving average is GBX 142.23 and its 200 day moving average is GBX 143.44. The stock’s market capitalization is GBX 48.13 million.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/panmure-gordon-reaffirms-buy-rating-for-midatech-pharma-plc-mtph.html
About Midatech Pharma PLC
Midatech Pharma PLC is an early-stage biopharmaceutical company that focuses on commercializing and developing products in oncology and other therapeutic areas. The Company’s segments include Pipeline Research and Development, and Commercial. The Pipeline Research and Development segment seeks to develop products using the nanomedicine and sustained release technology platforms.
Receive News & Ratings for Midatech Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Midatech Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.